All In Biotech

Drug Trial Radar · NCT05502341

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 689 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

689

Actual

Start

Aug 16, 2022

Primary completion

Sep 29, 2025

Study completion Dec 2029

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).

Conditions

  • HIV-1-infection

Interventions

  • BictegravirDrug

    Tablets administered orally without regard to food

  • LenacapavirDrug

    Tablets administered orally without regard to food

  • BIC/LEN FDCDrug

    Tablets administered orally without regard to food

  • Stable Baseline RegimenDrug

    SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva). * Nucleos(t)ide Reverse Transcriptase Inhibitors: * Abacavir * Emtricitabine * Lamivudine * Tenofovir alafenamide * Tenofovir disoproxil fumarate * Zidovudine * Non-Nucleosite Reverse Transcriptase Inhibitors: * Delavirdine * Efavirenz * Nevirapine * Rilpivirine * Doravirine * Integrase Inhibitors: * Bictegravir * Cabotegravir * Dolutegravir * Elvitegravir * Raltegravir * Protease Inhibitors: * Atazanavir * Darunavir * Fosamprenavir * Indinavir * Lopinavir * Nelfinavir * Saquinavir * Tipranavir * Chemokine Co-receptor 5 (CCR5) Antagonist: * Maraviroc * Fusion Inhibitors: * Enfuvirtide * gp120 Attachment Inhibitor: * Fostemsavir * Anti-CD4 Monoclonal Antibodies: * Ibalizumab-uiyk

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot AlgorithmTime frame: Week 24
  2. Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 48

Locations

94 sites in 15 countries. Site status is shown where the registry gives one.

  • Be Well Medical Center

    Berkeley, California

  • Pacific Oaks Medical Group

    Beverly Hills, California

  • Ruane Clinical Research Group, Inc

    Los Angeles, California

  • Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care

    Oakland, California

  • Bios Clinical Research

    Palm Springs, California

  • University of California San Diego (UCSD)

    San Diego, California

  • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center

    Torrance, California

  • The Men's Health Foundation

    West Hollywood, California

  • Denver Health Medical Center

    Denver, Colorado

  • Yale University; School of Medicine; AIDS Program

    New Haven, Connecticut

  • Midland Florida Clinical Research Center, LLC

    DeLand, Florida

  • Therafirst Medical Centers

    Fort Lauderdale, Florida

  • Gary Richmond, MD, PA, Inc.

    Fort Lauderdale, Florida

  • Midway Immunology & Research Center, LLC

    Ft. Pierce, Florida

  • Schiff Center for liver Diseases/University of Miami

    Miami, Florida

  • Floridian Clinical Research

    Miami Lakes, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Therapeutic Concepts, PA

    Orlando, Florida

  • Triple O Research Institute PA

    West Palm Beach, Florida

  • Atlanta ID Group

    Atlanta, Georgia

  • Mercer University School of Medicine

    Macon, Georgia

  • Howard Brown Health Center

    Chicago, Illinois

  • Kansas City Care Clinic

    Kansas City, Missouri

  • Southampton Healthcare, Inc.

    St Louis, Missouri

  • Saint Michael's Medical Center

    Newark, New Jersey

  • AXCES Research Group

    Santa Fe, New Mexico

  • New York Presbyterian Hospital

    Flushing, New York

  • Ricky K. Hsu, MD, PC

    New York, New York

  • University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina

  • East Carolina University

    Greenville, North Carolina

  • Philadelphia FIGHT

    Philadelphia, Pennsylvania

  • Medical University of South Carolina (MUSC) Research NEXUS

    Charleston, South Carolina

  • Central Texas Clinical Research

    Austin, Texas

  • St. Hope Foundation

    Bellaire, Texas

  • AIDS Arms, Inc., DBA Prism Health North Texas

    Dallas, Texas

  • North Texas Infectious Diseases Consultants

    Dallas, Texas

  • Texas Centers for Infectious Disease Associates

    Fort Worth, Texas

  • Gordon E. Crofoot MD PA

    Houston, Texas

  • Diagnostic Clinic of Longview - Center for Clinical Research

    Longview, Texas

  • Peter Shalit, MD

    Seattle, Washington

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.